Linked Life Data

2417331

Source:http://linkedlifedata.com/resource/pubmed/id/2417331

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4 Suppl 5
pubmed:dateCreated
1986-2-13
pubmed:abstractText
Renal-cell carcinoma rarely responds to cytotoxic chemotherapy, yet considerable evidence suggests that host factors may be capable of modifying the course of the disease. Although the mechanisms of interferon's antitumor effects are not well defined, the possibility that interferon might augment a host immune response provided a rationale for early clinical trials in this tumor. Investigations using various interferon alpha preparations (including interferons induced in human leukocytes and a human lymphoblastoid cell line) and recombinant interferons alfa-2a and alfa-2b have all provided evidence for antitumor activity. The overall major response rate with interferon alpha species in the 344 evaluable patients included in these 14 studies was 16.6% (57 patients), with response rates in individual studies ranging from 5% (1/21) to 31% (11/35). In renal-cell carcinoma, a response rate of the magnitude of 15% can be viewed with cautious optimism. Dose, schedule, route, and preparation have yet to be established for maximum efficacy, but progress has been made toward defining factors predicting response to treatment and mechanisms of interferon action.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0093-7754
pubmed:author
pubmed:issnType
Print
pubmed:volume
12
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
13-7
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
1985
pubmed:articleTitle
Therapeutic options in renal-cell carcinoma.
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, U.S. Gov't, P.H.S., Review, Research Support, Non-U.S. Gov't